[ADMS] Adamas Pharmaceuticals, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 17.42 Change: 0.78 (4.69%)
Ext. hours: Change: 0 (0%)

chart ADMS

Refresh chart

Description: Adamas Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapeutics targeting chronic disorders of the central nervous systems in the United States. The company?s lead product candidate, ADS-5102, is being developed for a complication of Parkinson?s disease, known as levodopa-induced dyskinesia, and as a treatment for chronic behavioral symptoms associated with traumatic brain injury. Its portfolio also includes an NDA-submitted fixed-dose combination product candidate, MDX-8704, which is being co-developed with Forest Laboratories, Inc.; and an approved controlled-release product, Namenda XR. The company was formerly known as NeuroMolecular Pharmaceuticals, Inc. and changed its name to Adamas Pharmaceuticals, Inc. in July 2007. Adamas Pharmaceuticals, Inc. was founded in 2000 and is headquartered in Emeryville, California.

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS-2.84 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters -99.1% Sales Growth - Q/Q-99.25% P/E-6.16
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA2.99% ROE3.2% ROI
Current Ratio14.25 Quick Ratio Long Term Debt/Equity Debt Ratio0.06
Gross Margin Operating Margin21.43% Net Profit Margin7.87% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities300 K Cash From Investing Activities-18.45 M Cash From Operating Activities-14.06 M Gross Profit
Net Profit-12.2 M Operating Profit-12.23 M Total Assets147.34 M Total Current Assets115.52 M
Total Current Liabilities8.11 M Total Debt Total Liabilities9.79 M Total Revenue230 K
Technical Data
High 52 week42.65 Low 52 week5.48 Last close5.73 Last change-3.86%
RSI31.77 Average true range0.3 Beta1.57 Volume92.31 K
Simple moving average 20 days-5.84% Simple moving average 50 days-15.11% Simple moving average 200 days-74%
Performance Data
Performance Week2.32% Performance Month-10.47% Performance Quart-76.34% Performance Half-81.62%
Performance Year-79.54% Performance Year-to-date-75.52% Volatility daily2.42% Volatility weekly5.41%
Volatility monthly11.1% Volatility yearly38.44% Relative Volume208.74% Average Volume562.75 K
New High New Low

News

2019-09-20 08:00:00 | Adamas Announces New Safety and Efficacy Data for GOCOVRI® in Parkinson’s Disease Patients with Dyskinesia at the Movement Disorder Society 2019 International Congress

2019-09-17 16:15:00 | Adamas Announces New Employment Inducement Grant

2019-09-13 07:51:36 | Easy Come, Easy Go: How Adamas Pharmaceuticals NASDAQ:ADMS Shareholders Got Unlucky And Saw 71% Of Their Cash Evaporate

2019-09-13 07:30:00 | Adamas Pharmaceuticals Appoints Neil McFarlane as Chief Executive Officer

2019-09-10 16:15:00 | Adamas Announces New Employment Inducement Grant

2019-08-12 17:07:38 | Adamas Announces New Employment Inducement Grant

2019-08-12 03:11:24 | Adamas Pharmaceuticals Inc ADMS Q2 2019 Earnings Call Transcript

2019-08-09 13:33:50 | Edited Transcript of ADMS earnings conference call or presentation 8-Aug-19 8:30pm GMT

2019-08-08 16:02:00 | Adamas Reports Second Quarter 2019 Financial Results

2019-08-08 11:11:09 | Need To Know: Adamas Pharmaceuticals, Inc. NASDAQ:ADMS Insiders Have Been Selling Shares

2019-08-01 10:33:02 | Adamas Pharmaceuticals ADMS May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

2019-07-29 09:43:01 | What's in Store for DENTSPLY SIRONA XRAY in Q2 Earnings?

2019-07-23 16:05:00 | Adamas to Announce Second Quarter 2019 Financial Results and Host Conference Call on August 8, 2019

2019-07-08 16:29:28 | Adamas Announces New Employment Inducement Grant

2019-07-08 09:24:01 | Top Ranked Momentum Stocks to Buy for July 8th

2019-07-05 08:35:12 | Bausch Gains 38.9% YTD on Product Launches & Debt Reduction

2019-06-28 20:37:54 | Hedge Funds Are Dumping Adamas Pharmaceuticals Inc ADMS

2019-06-28 18:50:00 | INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Adamas Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm

2019-06-27 12:00:00 | Lifshitz & Miller LLP Announces Investigation of Adamas Pharmaceuticals, Inc., ASGN Incorporated, Box, Inc., ChinaCache International Holdings Ltd, Mammoth Energy Services, Inc., Realogy Holdings Corp., Total System Services, Inc., and Verint Systems Inc.

2019-06-26 15:10:00 | IMPORTANT INVESTOR NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Adamas Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm

2019-06-25 08:10:12 | Will Adamas Pharmaceuticals Continue to Surge Higher?

2019-06-21 10:37:02 | Bausch Health BHC Catches Eye: Stock Jumps 6.2%

2019-06-20 09:56:48 | Should You Worry About Adamas Pharmaceuticals, Inc.'s NASDAQ:ADMS CEO Salary Level?

2019-06-20 09:51:01 | Allergan AGN in Focus: Stock Moves 6.2% Higher

2019-06-19 07:51:49 | The Daily Biotech Pulse: Positive Readouts From Adamas And Ironwood, Sesen Bio To Offer Shares, Stoke Therapeutics Debut

2019-06-18 16:05:10 | Adamas Announces Publication and Presentation of a Data Analysis Demonstrating GOCOVRI Reduces Both the Frequency and Duration of Daily Episodes of Troublesome Dyskinesia and OFF in Parkinson’s Disease

2019-06-18 09:00:01 | What Makes Adamas ADMS a New Buy Stock

2019-06-17 17:54:00 | ADMS INVESTORS NOTICE: Lieff Cabraser Investigates Claims Against Adamas Pharmaceuticals, Inc.

2019-06-17 17:23:57 | EQUITY ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Adamas Pharmaceuticals, Inc.

2019-06-12 20:20:00 | INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against Adamas Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

2019-06-12 19:05:15 | SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Adamas Pharmaceuticals, Inc. - ADMS

2019-06-11 13:00:00 | SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Adamas Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

2019-06-10 19:02:00 | SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Adamas Pharmaceuticals, Inc. - ADMS

2019-06-10 14:15:00 | IMPORTANT INVESTOR NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Adamas Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

2019-06-10 09:00:00 | ADMS INVESTORS ALERT: Lieff Cabraser Announces Securities Class Action Against Adamas Pharmaceuticals, Inc.

2019-06-07 18:20:00 | SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Adamas Pharmaceuticals, Inc. - ADMS

2019-06-07 17:30:00 | Adamas Announces New Employment Inducement Grant

2019-06-04 11:49:48 | ONGOING INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Adamas Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

2019-06-03 20:20:00 | SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Adamas Pharmaceuticals, Inc. - ADMS

2019-06-03 18:00:00 | ADAMAS INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Adamas Pharmaceuticals, Inc.’s January 24, 2018 Secondary Public Offering To Contact The Firm

2019-06-03 16:31:00 | Adamas to Present at Upcoming JMP Investor Conference

2019-05-31 11:45:18 | ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Adamas Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

2019-05-30 19:03:29 | SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Adamas Pharmaceuticals, Inc. - ADMS

2019-05-30 18:31:23 | ADAMAS INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Adamas Pharmaceuticals, Inc.’s January 24, 2018 Secondary Public Offering To Contact The Firm

2019-05-30 16:30:00 | Adamas Pharmaceuticals Welcomes Vijay Shreedhar as Chief Commercial Officer 

2019-05-29 10:32:00 | INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Adamas Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

2019-05-29 10:23:00 | SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Adamas Pharmaceuticals, Inc. ADMS

2019-05-28 21:00:00 | Bragar Eagel & Squire, P.C. is Investigating Adamas Pharmaceuticals, Inc. NASDAQ: ADMS on Behalf of Adamas Stockholders and Encourages Adamas Investors to Contact the Firm

2019-05-28 17:55:01 | EQUITY ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Adamas Pharmaceuticals, Inc.

2019-05-28 15:58:00 | INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Adamas Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm